Pazopanib in the treatment of advanced renal cell carcinoma

Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer in most countries of the world. Pazopanib inhibits tyrosine kinase receptors involved in tumor angiogenesis and proliferation, including VEGF, platelet-derived growth factor (PDGF) and stem cell growth...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: M. I. Volkova, A. S. Olshanskaya
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: Remedium Group LLC 2018-11-01
Sarja:Медицинский совет
Aiheet:
pazopanib
sorafenib
sunitinib
axitinib
bevacizumab
everolimus
disseminated renal cell carcinoma
targeted therapy
survival
Linkit:https://www.med-sovet.pro/jour/article/view/2753
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia